Biomarkers Markets, 2026 by Type (Safety, Efficacy, Validation), Disease (Cancer, Neurological), Application (Diagnostics, Drug Discovery & Development, Personalized Medicine) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Biomarkers Market by Product (Consumable, Service), Type (Safety, Efficacy, Validation), Disease (Cancer (Solid & Liquid Biopsy), Neurological), Application (Diagnostics, Drug Discovery & Development, Personalized Medicine) - Global Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

The global biomarkers market is expected to reach USD 78.1 billion in 2026 from USD 43.1 billion in 2021 at a CARG of 12.6%.

Growth in the biomarkers market is mainly driven by factors such as the growing importance of companion diagnostics, increasing prevalence of cancer worldwide, growing funding activities for biomarker research, and product innovations.

"By disease indications segment, the cancer segment accounted for the fastest-growing segment of the biomarkers market"

Based on disease indication, the biomarkers market is segmented into cancer, infectious diseases, neurological disorders, immunological disorders, cardiovascular disorders, and other disease indications. The cancer segment is expected to be the fastest-growing segment of the biomarkers market during the forecast period. The growth of this segment is primarily due to the increasing prevalence of cancer globally and the growing application of biomarkers in cancer diagnostics.

"By application, the diagnostics segment accounted for the largest share of the biomarkers market"

Based on application, the biomarkers market is segmented into diagnostics, drug discovery & development, personalized medicine, disease risk assessment, and other applications. In 2020, the diagnostics segment accounted for the largest share of the application segment in the biomarkers market. The use of biomarkers for the diagnosis of multiple diseases, including cancer, infectious diseases, cardiovascular disorders, and neurological disorders, is on the rise. The increasing use of biomarkers is a major factor that drives the growth of the diagnostics segment of the biomarkers market.

"Asia Pacific: The fastest-growing region in the biomarkers market."

The biomarkers market in the Asia Pacific region is projected to register the highest growth during the forecast period. The growth of this segment is primarily due to the increasing use of biomarkers for diagnostic purposes, the growing prevalence of chronic diseases, favorable government initiatives, and the growing focus on genomic & proteomic research projects.

"North America: the largest share of the biomarkers market"

North America accounted for the largest share of the market. The large share of this region can be attributed to the growing use of biomarkers in personalized medicine, various growth strategies adopted by key players with established pharmaceutical companies in this region, and a higher adoption rate of biomarkers for disease diagnostics, majorly in cancer diagnosis.

The biomarkers market is dominated by a few globally established players such as:

• Abbott Laboratories
• Anygenes
• Axon Medchem Bv
• Bio-Rad Laboratories, Inc.
• Bioagilytix Labs
• Biomarkerbay B. V.
• Biomerieux Sa
• Celerion
• Charles River Laboratories International, Inc.
• Diametra
• Ekf Diagnostics Holdings, plc
• Enzo Biochem, Inc.
• Eurofins Scientific
• F. Hoffmann-La Roche Ltd
• JSR Life Sciences, LLC
• Merck Kgaa
• Meso Scale Diagnostics, LLC.
• Microconstants, Inc.
• Northeast Bioanalytical Laboratories LLC.
• Perkinelmer, Inc.
• Products Offered
• Q2 Solutions LLC
• Qiagen N.V.
• Signosis, Inc.
• Stressmarq Biosciences Inc.
• Thermo Fisher Scientific Inc.

For more information about this report visit https://www.researchandmarkets.com/r/wnozl1

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900